Seamless Therapeutics
Company type: Clinical
Main focus: Programmable recombinases
Company stage: Pre-clinical
Diseases: Not disclosed
Genome-editing tool: Programmable designer recombinases
Funding stage: Seed Funding (12.5M)
Location: Dresden, Germany
Website: https://seamlesstx.com/#about_us
Pipeline: Not disclosed
Partners:
Seamless Therapeutics leverages forced evolution to generate target-specific recombinases to address several clinically-relevant conditions. Evolved recombinases hold the potential for safer, more precise, and more efficient genome editing without the need to induced target DNA double-stranded breaks.